Ignite Creation Date:
2024-05-06 @ 8:28 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06399172
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-03
First Post:
2024-04-23
Brief Title:
OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy
Sponsor:
OncoSil Medical Limited
Organization:
OncoSil Medical Limited
Study Overview
Official Title:
OncoSil Pancreatic Cancer Post-marketing Clinical Registry Italy
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
OSPRItaly
Brief Summary:
The OSPRItaly Patient Registry has been developed to assess the performance and safety of the OncoSil device when used within the approved indication of unresectable locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy within a real-world observational registry
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None